Dataset Information

Difructose dianhydride improves intestinal calcium absorption, wound healing, and barrier function.

ABSTRACT: The gastrointestinal tract (GIT) is critical for nutrient absorption and is an important barrier against harmful pathogens and antigens. Difructose anhydrides (DFA)-IVs are nondigestible disaccharides that enhance calcium and iron absorption by affecting the intestinal epithelial tissue. However, their effects on intestinal functions are not fully understood. In this study, we performed a feeding trial and found that dietary DFA-IVs improved growth performance, relative breast muscle and liver weight, and digestibility and blood calcium and iron concentrations in broilers. Additionally, dietary DFA-IVs increased expression of genes related to growth in the liver, muscle development, and absorption of calcium and iron in the intestine. In vitro experiments revealed that DFA-IV treatment improved intestinal wound-healing (migration, proliferation, and differentiation) after lipopolysaccharide (LPS) challenge in small intestinal epithelial cells. Furthermore, DFA-IV treatment enhanced the intestinal barrier function, which increased the transepithelial electrical resistance (TEER) and decreased the permeability of fluorescein isothiocyanate-dextran (FD-4) after LPS challenge in small intestinal epithelial cells. Collectively, these data indicate that DFA-IV could be used as a feed additive to enhance calcium and iron absorption by affecting the intestinal wound healing and permeability. This study may help improve our understanding of the molecular effects of DFA-IV on the intestine.

SUBMITTER: Lee SI

PROVIDER: S-EPMC5959885 | biostudies-other | 2018 May

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

Difructose dianhydride improves intestinal calcium absorption, wound healing, and barrier function.

Lee Sang In SI Kim In Ho IH

Scientific reports 20180518 1

The gastrointestinal tract (GIT) is critical for nutrient absorption and is an important barrier against harmful pathogens and antigens. Difructose anhydrides (DFA)-IVs are nondigestible disaccharides that enhance calcium and iron absorption by affecting the intestinal epithelial tissue. However, their effects on intestinal functions are not fully understood. In this study, we performed a feeding trial and found that dietary DFA-IVs improved growth performance, relative breast muscle and liver w ...[more]

PMID: 29777169

Similar Datasets

Project description:Alcohol liver disease (ALD) is a major cause of liver-related mortality globally, yet there remains an unmet demand for approved ALD drugs. The pathogenesis of ALD involves perturbations to the intestinal barrier and subsequent translocation of bacterial endotoxin that, acting through toll-like receptor 4 (TLR4), promotes hepatic inflammation and progression of ALD. In the present study we investigated the ability of fenretinide (Fen) [N-(4-hydroxyphenyl) retinamide], a synthetic retinoid with known anti-cancer and anti-inflammatory properties, to modulate intestinal permeability and clinical hallmarks of ALD in a mouse model of chronic ethanol (EtOH) exposure. Our results show that EtOH-treated mice had reductions in mRNA and protein expression of intestinal tight junction proteins, including claudin one and occludin, and increases in intestinal permeability and endotoxemia compared to pair-fed mice. Also, EtOH-treated mice had marked increases in hepatic steatosis, liver injury, and expression of pro-inflammatory mediators, including TNF-α, and TLR4-positive macrophages, Kupffer cells, and hepatocytes in the intestines and liver, respectively. In contrast, EtOH + Fen-treated mice were resistant to the effects of EtOH on promoting intestinal permeability and had higher intestinal protein levels of claudin one and occludin. Also, EtOH + Fen-treated mice had significantly lower plasma levels of endotoxin, and reductions in expression of TNF-α and TLR4 positive macrophages, Kupffer cells, and hepatocytes in the intestine and liver. Lastly, we found that EtOH + Fen-treated mice exhibited major reductions in hepatic triglycerides, steatosis, and liver injury compared to EtOH-treated mice. Our findings are the first to demonstrate that Fen possesses anti-ALD properties, potentially through modulation of the intestinal barrier function, endotoxemia, and TLR4-mediated inflammation. These data warrant further pre-clinical investigations of Fen as a potential anti-ALD drug.

Project description:BackgroundWe recently reported the clinical safety profile of RJX, a well-defined intravenous GMP-grade pharmaceutical formulation of anti-oxidant and anti-inflammatory vitamins as active ingredients, in a Phase 1 study in healthy volunteers (ClinicalTrials.gov Identifier: NCT03680105) (Uckun et al., Front. Pharmacol. 11, 594321. 10.3389/fphar.2020.594321). The primary objective of the present study was to examine the effects of GMP-grade RJX on wound and burn injury healing in diabetic rats.MethodsIn the present study, a rat model of T2DM was used that employs HFD in combination with a single injection of STZ intraperitoneally (i.p) at a moderate dose level (45 mg/kg). Anesthetized diabetic rats underwent full-thickness skin excision on the back or were subjected to burn injury via a heated brass probe and then started on treatments with normal saline (NS = vehicle) or RJX administered via intraperitoneal injections for three weeks.FindingsNotably, diabetic rats treated with the 1.25 mL/kg or 2.5 mL/kg RJX (DM+RJX groups) rapidly healed their wounds as fast as non-diabetic control rats. Inflammatory cell infiltration in the dermis along with fibrin and cell debris on the epithelial layer persisted for up to 14 days in the DM+NS group but not in RJX-treated groups. The histopathological score of wound healing on days 7 and 14 was better in diabetic rats treated with RJX than diabetic rats treated with NS and comparable to the scores for non-diabetic healthy rats consistent with an accelerated healing process. The residual wound area of RJX-treated rats was significantly smaller than that of NS-treated diabetic rats at each evaluation time point (P<0.001). The accelerating effect of RJX on diabetic wound healing was dose-dependent. We obtained similar results in the burn injury model. Our results demonstrate that RJX - at a dose level >10-fold lower than its clinical maximum tolerated dose (MTD) - accelerates the healing of excision wounds as well burn injury in diabetic rats.

Dataset Information

Difructose dianhydride improves intestinal calcium absorption, wound healing, and barrier function.

Publications

Difructose dianhydride improves intestinal calcium absorption, wound healing, and barrier function.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets